Hydroxychloroquine Therapy Led to the Diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in an Elderly Patient with COVID-19 Involvement: A Case Report and Review of the Literature

Razieh Taghizadeh-Sarvestani; Hamid Reihani; Ali Ghanei-Shahmirzadi; Alireza Keshtkar; Parsa Yazdanpanahi

doi:10.1155/2022/4749424

Hydroxychloroquine Therapy Led to the Diagnosis of Glucose-6-Phosphate Dehydrogenase (G6PD) Deficiency in an Elderly Patient with COVID-19 Involvement: A Case Report and Review of the Literature

Case Rep Med. 2022 Oct 3:2022:4749424. doi: 10.1155/2022/4749424. eCollection 2022.

Authors

Razieh Taghizadeh-Sarvestani¹, Hamid Reihani², Ali Ghanei-Shahmirzadi², Alireza Keshtkar², Parsa Yazdanpanahi²

Affiliations

¹ Department of Pediatric Neurology, Shiraz University of Medical Sciences, Shiraz, Iran.
² Student Research Committee, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common RBC abnormality, affecting 400 million people globally. Neonatal jaundice, hemolytic anemia, icteric skin, dark urine, and fever are usually the primary signs of this condition, which is generally diagnosed between the ages of infancy and 16 years old. Therefore, its first manifestation in old age is an unexpected phenomenon. Here, we present the case of a 70-year-old man with no past medical history of G6PD deficiency that was admitted to our hospital due to COVID-19 infection and developed acute hemolytic anemia while receiving hydroxychloroquine (HCQ) medication for COVID-19-related pneumonia.

Publication types

Case Reports